Opus Genetics is trading 6.13% higher in pre-market at $5.36, versus the September 28 close of $5.05; no clear catalyst has been identified. - The provided price context also shows a 6.09% gain in the prior session. - No verified September 29 company announcement or other clear catalyst was found. The latest listed release was September 9 clinical-trial news, with no established direct connection to the move. - Broader index moves are modest and do not clearly explain the move.